Biohit Oyj
OMXH:BIOBV
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.85
2.53
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one BIOBV stock under the Base Case scenario is 3.35 EUR. Compared to the current market price of 2.3 EUR, Biohit Oyj is Undervalued by 31%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Biohit Oyj
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for BIOBV cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Biohit Oyj
Balance Sheet Decomposition
Biohit Oyj
Current Assets | 12.9m |
Cash & Short-Term Investments | 5m |
Receivables | 6.9m |
Other Current Assets | 1m |
Non-Current Assets | 1.3m |
Long-Term Investments | 100k |
PP&E | 800k |
Intangibles | 400k |
Current Liabilities | 3m |
Accounts Payable | 800k |
Other Current Liabilities | 2.2m |
Non-Current Liabilities | 400k |
Long-Term Debt | 400k |
Earnings Waterfall
Biohit Oyj
Revenue
|
14m
EUR
|
Cost of Revenue
|
-5.4m
EUR
|
Gross Profit
|
8.6m
EUR
|
Operating Expenses
|
-6.9m
EUR
|
Operating Income
|
1.6m
EUR
|
Other Expenses
|
26k
EUR
|
Net Income
|
1.7m
EUR
|
Free Cash Flow Analysis
Biohit Oyj
EUR | |
Free Cash Flow | EUR |
BIOBV Profitability Score
Profitability Due Diligence
Biohit Oyj's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
Score
Biohit Oyj's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
BIOBV Solvency Score
Solvency Due Diligence
Biohit Oyj's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Biohit Oyj's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BIOBV Price Targets Summary
Biohit Oyj
According to Wall Street analysts, the average 1-year price target for BIOBV is 2.75 EUR with a low forecast of 2.73 EUR and a high forecast of 2.84 EUR.
Dividends
Current shareholder yield for BIOBV is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Biohit Oyj engages in the development, manufacture, and market of diagnostic tests and analysis systems. The company is headquartered in Helsinki, Etela-Suomen. The firm operates one business segment, named Diagnostics. The Diagnostics segment offers solutions for the early diagnosis and prevention of gastrointestinal diseases. The company provides blood-sample examination based on GastroPanel for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and Helicobacter pylori infection in connection with gastroscopy, as well as the ColonView examination for the early detection of fecal occult intestinal bleeding, which indicates a risk of colorectal cancer. The Company’s products are used in hospitals, healthcare centers and research institutions. The company operates primarily in Europe and Asia. Furthermore, the Company is a parent of Biohit Healthcare Ltd, Biohit Healthcare Srl, Oy Finio Ab, and Vantaan Hienomekano Oy, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one BIOBV stock under the Base Case scenario is 3.35 EUR.
Compared to the current market price of 2.3 EUR, Biohit Oyj is Undervalued by 31%.